U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H39ClN7O2P
Molecular Weight 584.0935
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BRIGATINIB

SMILES

CN1CCN(CC1)C2CCN(CC2)c3ccc(c(c3)OC)Nc4ncc(c(=Nc5ccccc5P(=O)(C)C)[nH]4)Cl

InChI

InChIKey=AILRADAXUVEEIR-UHFFFAOYSA-N
InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)

HIDE SMILES / InChI

Molecular Formula C29H39ClN7O2P
Molecular Weight 584.0935
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27780853

Brigatinib (AP26113) is an investigational, targeted cancer medicine discovered internally at ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It is in development for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell cancer (NSCLC) whose disease is resistant to crizotinib. Brigatinib is currently being evaluated in the global Phase 2 ALTA (ALK in Lung Cancer Trial of AP26113) trial that is anticipated to form the basis for its initial regulatory review. ARIAD has also initiated the Phase 3 ALTA 1L trial to assess the efficacy of brigatinib in comparison to crizotinib. Brigatinib was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) in May 2016 for the treatment of certain subtypes of non-small cell lung cancer (NSCLC). The designation is for anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC). Brigatinib received breakthrough therapy designation from the FDA in October 2014 for the treatment of patients with ALK+ NSCLC whose disease is resistant to crizotinib. Both designations were based on results from an ongoing Phase 1/2 trial that showed anti-tumor activity of brigatinib in patients with ALK+ NSCLC, including patients with active brain metastases.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ALUNBRIG

Approved Use

ALUNBRIG is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Launch Date

1493251200000
Primary
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
552 ng/mL
180 mg 1 times / day steady-state, oral
dose: 180 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BRIGATINIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
701.3 ng/mL
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIGATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
8165 ng × h/mL
180 mg 1 times / day steady-state, oral
dose: 180 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BRIGATINIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
13261 ng × h/mL
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIGATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
25 h
180 mg 1 times / day steady-state, oral
dose: 180 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BRIGATINIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
31 h
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIGATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
34%
180 mg 1 times / day steady-state, oral
dose: 180 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BRIGATINIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Disc. AE: Pneumonitis, Pneumonitis...
Other AEs: Nausea, Nausea...
AEs leading to
discontinuation/dose reduction:
Pneumonitis (all grades, 37%)
Pneumonitis (grade 3-4, 1.8%)
Hypertension (grade 3-4, 5.5%)
Pneumonia (all grades, 4.6%)
Pneumonia (grade 3-4, 1.83%)
Hyperglycemia (grade 3-4, 3.7%)
Creatine phosphokinase increased (all grades, 27%)
Creatine phosphokinase increased (grade 3-4, 2.8%)
Other AEs:
Nausea (all grades, 33%)
Nausea (grade 3-4, 0.9%)
Diarrhea (all grades, 19%)
Vomiting (all grades, 24%)
Vomiting (grade 3-4, 1.8%)
Constipation (all grades, 19%)
Constipation (grade 3-4, 0.9%)
Abdominal distension (all grades, 17%)
Abdominal pain (all grades, 17%)
Epigastric discomfort (all grades, 17%)
Asthenia (all grades, 29%)
Asthenia (grade 3-4, 1.8%)
Fatigue (all grades, 29%)
Fatigue (grade 3-4, 1.8%)
Pyrexia (all grades, 14%)
Cough (all grades, 18%)
Dyspnea (all grades, 27%)
Dyspnea (grade 5, 1 patient)
Exertional dyspnea (all grades, 27%)
Dyspnea (grade 3-4, 2.8%)
Exertional dyspnea (grade 3-4, 2.8%)
Hypoxia (all grades, 0.9%)
Headache (all grades, 28%)
Sinus headache (all grades, 28%)
Peripheral sensory neuropathy (all grades, 13%)
Paresthesia (all grades, 13%)
Peripheral sensory neuropathy (grade 3-4, 0.9%)
Paresthesia (grade 3-4, 0.9%)
Acneiform dermatitis (all grades, 15%)
Exfoliative rash (all grades, 15%)
Rash (all grades, 15%)
Pruritic rash (all grades, 15%)
Pustular rash (all grades, 15%)
Acneiform dermatitis (grade 3-4, 1.8%)
Exfoliative rash (grade 3-4, 1.8%)
Rash (grade 3-4, 1.8%)
Pruritic rash (grade 3-4, 1.8%)
Pustular rash (grade 3-4, 1.8%)
Hypertension (all grades, 11%)
Muscle spasms (all grades, 12%)
Back pain (all grades, 10%)
Back pain (grade 3-4, 1.8%)
Musculoskeletal pain (all grades, 9.2%)
Myalgia (all grades, 9.2%)
Arthralgia (all grades, 14%)
Arthralgia (grade 3-4, 0.9%)
Pain in extremity (all grades, 11%)
Decreased appetite (all grades, 22%)
Decreased appetite (grade 3-4, 0.9%)
Diplopia (all grades, 7.3%)
Photophobia (all grades, 7.3%)
Blurred vision (all grades, 7.3%)
Visual acuity reduced (all grades, 7.3%)
Visual impairment (all grades, 7.3%)
Vitreous floaters (all grades, 7.3%)
Visual field defect (all grades, 7.3%)
Macular edema (all grades, 7.3%)
Vitreous detachment (all grades, 7.3%)
Pneumonia (grade 5, 1 patient)
Insomnia (all grades, 11%)
Aspartate aminotransferase increased (all grades, 38%)
Aspartate aminotransferase increased (grade 3-4, 0.9%)
Hyperglycemia (all grades, 38%)
Lipase increased (all grades, 21%)
Lipase increased (grade 3-4, 4.6%)
Alanine aminotransferase increased (all grades, 34%)
Amylase increased (all grades, 27%)
Amylase increased (grade 3-4, 3.7%)
Alkaline phosphatase increased (all grades, 15%)
Alkaline phosphatase increased (grade 3-4, 0.9%)
Phosphate decreased (all grades, 15%)
Phosphate decreased (grade 3-4, 1.8%)
Anemia (all grades, 23%)
Anemia (grade 3-4, 0.9%)
Lymphopenia (all grades, 19%)
Lymphopenia (grade 3-4, 2.8%)
Respiratory failure (grade 5, 1 patient)
Pulmonary embolism (grade 5, 1 patient)
Bacterial meningitis (grade 5, 1 patient)
Urosepsis (grade 5, 1 patient)
Sources:
300 mg 1 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy
DLT: Dyspnea, Hypoxia...
Dose limiting toxicities:
Dyspnea (1 patient)
Hypoxia (1 patient)
Sources:
240 mg 1 times / day multiple, oral
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
unhealthy
DLT: Alanine aminotransferase increased...
Dose limiting toxicities:
Alanine aminotransferase increased (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypoxia all grades, 0.9%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Back pain all grades, 10%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Hypertension all grades, 11%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Insomnia all grades, 11%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pain in extremity all grades, 11%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Muscle spasms all grades, 12%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Paresthesia all grades, 13%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Peripheral sensory neuropathy all grades, 13%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Arthralgia all grades, 14%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pyrexia all grades, 14%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Acneiform dermatitis all grades, 15%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Alkaline phosphatase increased all grades, 15%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Exfoliative rash all grades, 15%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Phosphate decreased all grades, 15%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pruritic rash all grades, 15%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pustular rash all grades, 15%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Rash all grades, 15%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Abdominal distension all grades, 17%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Abdominal pain all grades, 17%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Epigastric discomfort all grades, 17%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Cough all grades, 18%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Constipation all grades, 19%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Diarrhea all grades, 19%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Lymphopenia all grades, 19%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Lipase increased all grades, 21%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Decreased appetite all grades, 22%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Anemia all grades, 23%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Vomiting all grades, 24%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Amylase increased all grades, 27%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Dyspnea all grades, 27%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Exertional dyspnea all grades, 27%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Creatine phosphokinase increased all grades, 27%
Disc. AE
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Headache all grades, 28%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Sinus headache all grades, 28%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Asthenia all grades, 29%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Fatigue all grades, 29%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Nausea all grades, 33%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Alanine aminotransferase increased all grades, 34%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pneumonitis all grades, 37%
Disc. AE
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Aspartate aminotransferase increased all grades, 38%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Hyperglycemia all grades, 38%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pneumonia all grades, 4.6%
Disc. AE
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Blurred vision all grades, 7.3%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Diplopia all grades, 7.3%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Macular edema all grades, 7.3%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Photophobia all grades, 7.3%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Visual acuity reduced all grades, 7.3%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Visual field defect all grades, 7.3%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Visual impairment all grades, 7.3%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Vitreous detachment all grades, 7.3%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Vitreous floaters all grades, 7.3%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Musculoskeletal pain all grades, 9.2%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Myalgia all grades, 9.2%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Alkaline phosphatase increased grade 3-4, 0.9%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Anemia grade 3-4, 0.9%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Arthralgia grade 3-4, 0.9%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Aspartate aminotransferase increased grade 3-4, 0.9%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Constipation grade 3-4, 0.9%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Decreased appetite grade 3-4, 0.9%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Nausea grade 3-4, 0.9%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Paresthesia grade 3-4, 0.9%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Peripheral sensory neuropathy grade 3-4, 0.9%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Acneiform dermatitis grade 3-4, 1.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Asthenia grade 3-4, 1.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Back pain grade 3-4, 1.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Exfoliative rash grade 3-4, 1.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Fatigue grade 3-4, 1.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Phosphate decreased grade 3-4, 1.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pruritic rash grade 3-4, 1.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pustular rash grade 3-4, 1.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Rash grade 3-4, 1.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Vomiting grade 3-4, 1.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pneumonitis grade 3-4, 1.8%
Disc. AE
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pneumonia grade 3-4, 1.83%
Disc. AE
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Dyspnea grade 3-4, 2.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Exertional dyspnea grade 3-4, 2.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Lymphopenia grade 3-4, 2.8%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Creatine phosphokinase increased grade 3-4, 2.8%
Disc. AE
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Amylase increased grade 3-4, 3.7%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Hyperglycemia grade 3-4, 3.7%
Disc. AE
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Lipase increased grade 3-4, 4.6%
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Hypertension grade 3-4, 5.5%
Disc. AE
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Bacterial meningitis grade 5, 1 patient
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Dyspnea grade 5, 1 patient
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pneumonia grade 5, 1 patient
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Pulmonary embolism grade 5, 1 patient
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Respiratory failure grade 5, 1 patient
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Urosepsis grade 5, 1 patient
180 mg 1 times / day steady, oral
Recommended
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 18 - 82 years)
Health Status: unhealthy
Age Group: 54 years (range: 18 - 82 years)
Sex: M+F
Sources:
Dyspnea 1 patient
DLT, Disc. AE
300 mg 1 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Hypoxia 1 patient
DLT, Disc. AE
300 mg 1 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Alanine aminotransferase increased 1 patient
DLT
240 mg 1 times / day multiple, oral
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
unhealthy
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
unlikely
Comment: Induction of CYP3A4 mRNA (mean 6-fold change at 1 μM), but no induction of CYP3A4 activity.
Page: -
yes
yes
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Coadministration of gemfibrozil (a strong CYP2C8 inhibitor) 600 mg BID with a single dose of 90 mg brigatinib decreased brigatinib AUC by 12% (90% CI: 6%, 17%) and Cmax by 41% (90% CI: 35%, 46%) as compared with brigatinib alone.
Page: -
minor
yes (co-administration study)
Comment: Coadministration of itraconazole (a strong CYP3A4 inhibitor) increased brigatinib AUC by 2-fold. Coadministration of rifampin (a strong CYP3A4 inducer) decreased brigatinib AUC by 80% (90% CI: 79%, 82%) and Cmax by 60%
Page: -
no
no
no
no
no
no
no
no
no
yes
yes
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
2016 May 17
Patents

Patents

Sample Use Guides

90 mg tablet, taken orally once daily,continuously in a 28-day cycle
Route of Administration: Oral
Brigatinib inhibited ALK phosphorylation in a dose-dependent manner, and at 50 nM brigatinib, phosphorylation of ALK was abolished in ALK addicted neuroblastoma lines
Substance Class Chemical
Created
by admin
on Sat Jun 26 16:27:30 UTC 2021
Edited
by admin
on Sat Jun 26 16:27:30 UTC 2021
Record UNII
HYW8DB273J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BRIGATINIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
BRIGATINIB [ORANGE BOOK]
Common Name English
BRIGATINIB [WHO-DD]
Common Name English
AP26113
Code English
5-CHLORO-N4-(2-(DIMETHYLPHOSPHORYL)PHENYL)-N2-(2-METHOXY-4-(4-(4-METHYLPIPERAZIN-1- YL)PIPERIDIN-1-YL)PHENYL)PYRIMIDINE-2,4-DIAMINE
Systematic Name English
BRIGATINIB [USAN]
Common Name English
(2-((5-CHLORO-2-((2-METHOXY-4-(4-(4-METHYLPIPERAZIN-1-YL)PIPERIDIN-1-YL)PHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)PHENYL)DIMETHYL-,.DELTA.5-PHOSPHANONE
Systematic Name English
2,4-PYRIMIDINEDIAMINE, 5-CHLORO-N4-(2-(DIMETHYLPHOSPHINYL)PHENYL)-N2-(2-METHOXY-4-(4-(4-METHYL-1-PIPERAZINYL)-1-PIPERIDINYL)PHENYL)-
Systematic Name English
ALUNBRIG
Brand Name English
AP-26113
Code English
BRIGATINIB [MI]
Common Name English
BRIGATINIB [INN]
Common Name English
Classification Tree Code System Code
WHO-ATC L01XE43
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
FDA ORPHAN DRUG 505415
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
NDF-RT N0000175605
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
NCI_THESAURUS C1967
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL3545311
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
CAS
1197953-54-0
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
DRUG CENTRAL
5233
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
LACTMED
Brigatinib
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
NCI_THESAURUS
C98831
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
FDA UNII
HYW8DB273J
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
DRUG BANK
DB12267
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
WIKIPEDIA
Brigatinib
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
RXCUI
1921217
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
PUBCHEM
68165256
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
INN
10085
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
EVMPD
SUB184911
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
MERCK INDEX
M12099
Created by admin on Sat Jun 26 16:27:31 UTC 2021 , Edited by admin on Sat Jun 26 16:27:31 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
INHIBITOR
IC50
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
FECAL
TARGET -> INHIBITOR
IC50
EXCRETED UNCHANGED
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Volume of Distribution